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NOD2 activation by muramyl dipeptide causes a proinﬂammatory immune response in which the
adaptor protein CARD9 works synergistically with NOD2 to drive p38 and c-Jun N-terminal kinase
(JNK) signalling. To date the nature of the interaction between NOD2 and CARD9 remains undeter-
mined. Here we show that this interaction is not mediated by the CARDs of NOD2 and CARD9 as pre-
viously suggested, but that NOD2 possesses two interaction sites for CARD9; one in the CARD–NACHT
linker and one in the NACHT itself.
Structured summary of protein interactions:
NOD2 physically interacts with CARD9 by anti tag coimmunoprecipitation (View interaction)
 2014 The Authors. Published by Elsevier B.V. on behalf of the Federation of European Biochemical
Societies. This is an open access article under the CC BY license (http://creativecommons.org/licenses/
by/3.0/).1. Introduction
The cytoplasmic proteins NOD (nucleotide-binding oligomeri-
sation domain containing) 1 and NOD2 are members of the NLR
(nucleotide-binding, leucine-rich repeat containing receptor) fam-
ily of pattern recognition receptors. They act as immune sentinels
and play an important role in combating bacterial infection and
maintaining cellular homeostasis [1]. NOD1 and NOD2 recognise
fragments of bacterial peptidoglycan via their C-terminal leucine
rich repeats [2–5]. Activation causes conformational change and
relocalisation to the plasma membrane [6–9]. NF-jB (nuclear fac-
tor kappa B)-mediated pro-inﬂammatory signalling pathways are
activated following interaction between the CARDs (caspase
activation and recruitment domain) of NOD1/2 with their adaptorprotein RIP2 (receptor interacting protein 2). Understanding how
NOD1/2 signalling is regulated is important for the future develop-
ment of therapeutic treatments targeting inﬂammatory disorders
such as Crohn’s Disease.
CARD9 is an important adaptor molecule in the innate immune
response. CARD9 is predominantly associated with NF-jB signal-
ling pathways following stimulation of C-type lectin receptors like
DECTIN-1 [10,11]. Receptor ligation upregulates Spleen tyrosine
kinase (SYK) and activates Protein Kinase C delta which phosphor-
ylates Thr231 in CARD9 [12]. This causes formation of a CARD9/B
Cell lymphoma 10 (Bcl-10)/Mucosa-associated lymphoid tissue
lymphoma translocation protein 1 (Malt1) ‘signalosome’ which
activates NF-jB [10,13]. CARD9 is also involved in NF-jB signalling
downstream of the Retinoic acid-inducible gene I receptor (RIG-1)
family [14]. The biological function of CARD9 is conserved between
mice and humans. Human CARD9 is able to restore signalling in
murine Card9 knock-out cells [15] and both inactive human CARD9
mutant cells and murine Card9 knockout cells display a defective
response to b-glucan stimulation [15,16]
Recently, Hsu and colleagues demonstrated in mice that CARD9
is required for the synergistic activation of p38 and JNK (c-Jun N-
terminal kinase) following stimulation of NOD2 by either muramyl
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NOD2 and CARD9 was enhanced by the presence of RIP2 in both
over-expression and endogenous systems [17]. The relationship
between CARD9 and NOD2 is particularly intriguing as the genes
for both these proteins contain polymorphisms inﬂuencing suscep-
tibility to Crohn’s Disease in humans [18,19].
Multiprotein complexes play a key role in innate immune sig-
nalling. Complexes such as the inﬂammasome and Myddosome
are formed through interactions between members of the death
domain superfamily [20], which includes CARDs. NOD2 and CARD9
have two and one N-terminal CARDs respectively. We have used
cell-based immunoprecipitation and co-puriﬁcation of overexpres-
sed recombinant protein to study the molecular details of the
interaction between NOD2 and CARD9. Unexpectedly, we did not
ﬁnd any evidence for an interaction between the CARDs of NOD2
and CARD9 as previously suggested. Instead, we show that
the region in NOD2 responsible for the interaction with CARD9
involves the NACHT domain and the preceding linker to the
CARDs.
2. Materials and methods
2.1. Plasmids
Full length murine CARD9 (GENBANK: NP_001032836.1) with a
C-terminal V5-His epitope tag in the pEF6 expression vector (pEF6-
mCARD9-V5) was a kind gift from David Underhill [11]. Full-length
human NOD1 (GENBANK: AAD28350.1) and NOD2 (GENBANK:
AAG33677.1) with an N-terminal FLAG tag in a pCMV backbone
(pCMV-FLAG-NOD1 and pCMV-FLAG-NOD2) were kindly provided
by Thomas Kufer [21]. Single nucleotide polymorphisms (SNP)
across the NACHT domain were identiﬁed in the NCBI SNP data-
base and cloned into full-length pCMV-FLAG-NOD2 using site-
directed mutagenesis. N-terminal and C-terminal NOD2 constructs
were also generated by site-directed mutagenesis. GB1-RIP2–CARD
(human) and the tandem human NOD2 CARD construct used for
NMR chemical shifts have been described previously [22]. The
CARD of Card9 (residues 6-100), the tandem CARDs of NOD2
(residues 28-215) and the RIP2 CARD (residues 432-534) were
ampliﬁed by PCR and inserted, using Gateway cloning, into
the expression plasmid pDEST-HisMBP [23]. In addition to the
N-terminal His6-MBP (maltose binding protein) fusion each
construct included a C-terminal FLAG tag to further aid expres-
sion and stability. The CARD of murine CARD9 was also inserted
into pDEST-17 to generate an N-terminally 6His tagged
construct.
2.2. Immunoprecipitation
HEK 293T cells were maintained in DMEM (Sigma) supple-
mented with 10% FCS, 100 lg/ml Penicillin/Streptomycin and
2 mM L-glutamine at 37 C and 5% CO2. Cells were seeded in 6 well
plates and transfected using jetPEI (Polyplus Transfection) with
1 lg/well of full-length, mutated, or truncated pCMV-FLAG-
NOD2, or full-length pCMV-FLAG-NOD1, and 1 lg pEF6-mCARD9-
V5. After 24 h cells were washed twice in 1  PBS and lysed in
300 ll RIPA buffer (50 mM Tris–HCl pH 7.6, 150 mM NaCl, 0.25%
Triton X-100, 0.1% SDS, 0.5% sodium deoxycholate) supplemented
with 1  Protease Inhibitor Cocktail set V (Calbiochem) and 7.5
units of Benzonase nuclease (Sigma) per well. Lysates were incu-
bated on ice for 10 min with shaking and clariﬁed by centrifugation
(16000g; 2 min; 20 C). Cells were lysed and incubated with Pro-
tein G coated magnetic Dynabeads (Life Technologies) coupled to
mouse anti-FLAG antibody (Sigma). Immunoprecipitated proteins
and inputs were detected by western blot analysis using: rabbit
anti-ﬂag (Sigma), mouse anti-V5 (Abcam) and mouse anti-GAPDH(Abcam) primary antibodies and goat anti-rabbit (Abcam) or goat
anti-mouse (Sigma) secondary antibodies.
2.3. Recombinant protein expression and co-sonication pull-down
assays
Recombinant proteins were expressed in 10 ml cultures of
Rosetta2 Escherichia coli for 16 hr at 22 C except for GB1-RIP2–
CARD which used 4 h at 37 C. Cultures were pelleted, frozen over-
night and resuspended in standard lysis buffer (100 mM NaCl,
25 mM sodium phosphate, 20 mM imidazole, 5 mM b-mercap-
toethanol, 0.1 % Triton-X100). Appropriate samples were combined
and sonicated on ice. Insoluble debris was removed by centrifuga-
tion (16000g, 4 C, 10 min) and proteins puriﬁed using amylose
afﬁnity chromatography. Eluted samples were visualised by Coo-
massie Brilliant Blue staining.
2.4. NMR chemical shift assays
Samples of unlabelled murine CARD9 CARD and 15N-labelled
human NOD2 (28–218) were buffer exchanged overnight into
20 mM sodium phosphate (pH 7.1), 100 mM NaCl and 5 mM DTT.
1D (1H) and 2D (1H/15N) HSQC NMR spectra were recorded on a
Bruker Avance spectrometer at 600 MHz proton frequencies and
processed using an associated software package. All spectra were
recorded at 180 lM sample concentration (with 10% added D2O)
and at 298 K.
2.5. Homology modelling and bioinformatics
Residues 217–820, corresponding to residues encoded by the
large, central exon of human NOD2, were submitted to the PHYRE2
server for automatedmodelling [24]. Only one NLR NACHT structure,
the 4KXF structure of NLRC4 [25], is available in the PDB at present
and this was used as a template. Inspection of the resulting align-
ment and model showed that while the NBD, HD1 and WH domains
(217–632) were clearly homologous between NOD2 and NLRC4, the
rest of the exon, which forms HD2 and part of the LRR domain in
NLRC4, showed amore ambiguous alignment and so was not consid-
ered further. The ﬁnal model represents NOD2 residues A217–C632.
Homology models of the CARD of murine CARD9 and human
CARD9 from residue 6–100 were built using the CARD from
CARD11 (PDB 1D: 4I16) [26] as a template. Models were generated
using the model-default script from the MODELLER package v9.12
(http://salilab.org/modeller/).
The amino acid sequences of full length murine CARD9
(GENBANK: NP_001032836.1) and human CARD9 (GENBANK:
NP_43470.2) were aligned and the percentage identity and similar-
ity calculated using Clustal Omega [27].
3. Results
3.1. There is no interaction between the CARDs of NOD2 and CARD9
CARD-mediated protein–protein interactions play an important
role in numerous immune signalling pathways such as RIG-1 med-
iated viral sensing, inﬂammasome formation and facilitating
NOD1/2-mediated NF-jB signalling via RIP2 [28–30]. NOD2 and
CARD9, which both possess CARDs, work synergistically to drive
p38 and JNK signalling following activation of NOD2 and have been
shown to interact [17]. Currently nothing is known about how
this interaction is mediated, although theoretical models have
suggested the involvement of CARD:CARD interactions [31].
To test whether the NOD2 CARD9 interaction is CARD-mediated
we expressed the CARDs of human NOD2, murine CARD9 and human
RIP2 as recombinant proteins fused to solubility-enhancement and
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of the protocol established to study interactions between the
CARDs of NOD2 and RIP2 [22]. Speciﬁcally, bacterial cultures
containing overexpressed recombinant protein were resuspended
and combined prior to sonication. Amylose resin based afﬁnity
chromatography was used to purify proteins fused to MBP and
co-purifying interacting proteins were detected by Coomassie
Brilliant Blue staining following SDS–PAGE.
Consistent with previous work the NOD2 CARDs successfully
pulled down the RIP2 CARD, which was also capable of mediating
homomeric RIP2 interactions (Fig. 1A). However, we detected no- -
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Fig. 1D and E). However, there are no signiﬁcant chemical shift
changes in the presence of equimolar CARD9 CARD indicating that
there is no interaction between the two recombinant proteins
under the conditions studied (Fig. 1D and E (right panel)). Togetherthese approaches conclusively support the view that the CARDs of
NOD2 and CARD9 do not directly interact.
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ogy models of the two CARDs conﬁrmed that four of the ﬁve
substitutions were in helix 1 and the ﬁfth in helix 6. None of the
mutations affect the overall protein fold or the electrostatic prop-
erties of the CARDs (Supplementary Fig. 1B and C). This is consis-
tent with the conserved biological function of the molecules and
allows us to conclude that it is highly unlikely that the CARDs of
human CARD9 and human NOD2 would interact either.
3.2. The NACHT and CARD–NACHT linker of NOD2 are important
for interaction with CARD9
Given the inability of the respective CARDs to interact we used
domain truncations of FLAG-tagged NOD2 to map the region
required for interaction with CARD9. HEK293 cells were transiently
transfected with NOD2 truncations and V5-tagged CARD9 and
proteins immunoprecipitated after 24 h. CARD9 was immunopre-
cipitated by full-length, CARD–NACHT, and NACHT–LRR NOD2
constructs (Fig. 2A). Neither the CARDs nor the LRRs alone inter-
acted with CARD9, suggesting that the NACHT domain of NOD2
has a critical role in mediating interaction with CARD9.
To further investigate the importance of the NOD2 NACHT
domain we tested the impact of a panel of Crohn’s Disease associ-
ated single nucleotide polymorphisms (SNP) [33–36] spanning theNACHT on the interaction with CARD9. This included the widely
studied R702W SNP. We also tested the hyperactive Blau Syn-
drome associated SNP R334W [37]. All of the polymorphisms still
interacted with CARD9 indicating that these residues, and poten-
tially the surrounding regions of the NACHT, were not crucial for
CARD9 interaction (Fig. 2B and C). It also demonstrates that the
clinical impact of the R334W and R702W SNPs is unlikely to result
from alteration of the CARD9 and NOD2 interaction. Interestingly,
the W355stop SNP, which lacks any sequence downstream of this
tryptophan, still immunoprecipitated Card9 suggesting that a
region between the NOD2 CARDs andW355 could mediate interac-
tion. Consequently, we generated further C-terminal NOD2 trunca-
tions (Fig. 3A) and tested their interaction with CARD9. All of these
truncations, including A274stop which lacks any of the NACHT,
retained the ability to interact with CARD9 (Fig. 3B). Together with
the failure of the CARD only construct (residues 1–227; Figs. 2A
and 3B) to interact with CARD9 this indicated that residues 228–
274 contain a critical region for CARD9 interaction.
To characterise the role of the CARD–NACHT linker in more
detail we expanded our range of mutants to alter the amount of
linker present (Fig. 3A). Extension of the C-terminus of the CARD
only construct to residue 240 did not result in interaction with
CARD9 (Fig. 3B). However, addition of a further twenty residues,
to position 260, resulted in CARD9 being immunoprecipitated,
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truncations (Fig. 3B). All of our N-terminal truncations were able
to immunoprecipitate CARD9, including a construct beginning at
274 which therefore lacks the CARD–NACHT linker (Fig. 3B).
Intriguingly both the constructs 1–274 and 274–1040 interacted
with Card9 thereby implying the presence of at least two binding
sites in NOD2 for CARD9; one located in the CARD–NACHT linker
(between residues 241 and 274) and the other in the NACHT
domain.
Together these results support an interaction between NOD2
and CARD9. This interaction is not mediated by the CARD domains,
but instead involves two regions in NOD2 – one linking the CARDs
and NACHT, the other within the NACHT itself.4. Discussion
The pattern recognition receptors NOD1 and NOD2 play an
important role in the pro-inﬂammatory immune response to bac-
terial infections. Their ability to activate NF-jB-mediated tran-
scription following interaction with RIP2 has been widely
studied. Our understanding of how these receptors activate alter-
native signalling pathways, such as those utilising p38 and JNK,
is limited. However, it has been previously shown in mice that
engagement of the adaptor protein CARD9 is crucial in facilitating
NOD2-initiated p38 and JNK signalling, with the two proteins
working in synergy to mediate this response [17]. How this is
achieved, and how NOD2 and CARD9 interact has not previously
been understood. In this work we have identiﬁed two regions of
NOD2 capable of binding CARD9; one in the linker connecting
the CARDs and the NACHT, and one in the NACHT itself. These
binding surfaces may by spatially adjacent to one another in the
tertiary structure of the protein. A random mutagenesis study of
NOD2 identiﬁed two residues, A232 and V256, in the linker region
that whenmutated resulted in a signiﬁcant loss of NF-jB signalling
[38]. Whilst for A232 this correlated with a loss in protein expres-
sion this was not the case for V256, suggesting that the linker may
be more important for NOD2 functionality than previously
assumed. Somewhat surprisingly and despite the known impor-
tance of CARDs in mediating protein–protein interaction in
immune signalling complexes we saw no evidence that the CARDs
of NOD2 and CARD9 could interact with one another.
In this study we used murine CARD9 and human NOD2. In light
of the conserved biological function [15,16]; the high level of
sequence identity (Supplementary Fig. 1A); and the conserved nat-
ure of the electrostatic surfaces (Supplementary Fig. 1C) between
the human and murine proteins we are conﬁdent that our observa-
tions and conclusions remain valid for interactions between
human CARD9 and NOD2.
Our observations raise interesting questions about the molecular
composition and formation of the NOD2:CARD9 signalling complex.
The lack of NOD2 CARD9 CARD-mediated interaction suggests that
NOD2 could interact concurrently with RIP2, via its CARDs, and with
CARD9 via its linker/NACHT. This would enable simultaneous activa-
tion of NF-jB, p38 and JNK signalling pathways from the same mac-
romolecular complex. Hsu and colleagues reported that the presence
of RIP2 enhances the interaction between NOD2 and CARD9
[17].This could be through promotion of conformational changes
due to receptor activation which expose the CARD9 binding motifs
on NOD2; or by promoting protein clustering and thereby increasing
the avidity of the NOD2:CARD9 interaction. CARD9 contains a pre-
dicted coiled-coil domain (CCD). CCDs are widely reported to medi-
ate protein–protein interactions and it remains entirely feasible that
the CCD mediates interaction with NOD2. However, difﬁculties in
expressing the CCD independently of the CARD [32] have made this
hypothesis impractical to test to date.In conclusion, we have identiﬁed regions of NOD2 important for
CARD9 interaction. These now require functional interrogation to
determine precisely how the two proteins interact and whether
these regions could serve as modulators of receptor signalling with
the potential for the regulation of a range of signalling pathways.
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